Immunoassay Specimen Types:
Many immunoassays are performed on blood (serum or plasma) specimens. Physicians draw blood at the office, hospital clinic, or other locations, and send samples to laboratories for testing.
Urine has a long history as a diagnostic sample. Urine-based tests are available for tests including pregnancy, ovulation, and menopause tests, as well as for sexually transmitted diseases and drugs of abuse testing. In addition, non-lateral flow tests such as POC urine analyzers and biochemical-based POC urinalysis tests have been available for many years.
Saliva-based diagnostics have long enjoyed industry attention. Saliva-based POC tests are available for selected tests as HIV, alcohol, and drugs of abuse. Nucleic acids are present in saliva, and saliva samples are DNA sources for genotyping analysis. Centralized laboratories use saliva specimens for other analytes including hormones.
Saliva contains proteins (including antibodies), nucleic acids, and hormones. Saliva glands produce many analytes actually found in saliva samples, into which blood can also pass. Mechanisms including passive diffusion or active transport of molecules can cause this. Analytes found in blood can also be found in saliva, generating industry interest in saliva as a diagnostic specimen. As a diagnostic specimen, saliva is noninvasive and does not require highly trained specialists to perform. Specimens are also easy to both store and transport.
Saliva is an attractive test sample for diagnostics companies that are considering utilizing it for new test applications. Considerations will include test accuracy, cost effectiveness, and the outcome of research to identify and validate new biomarkers in saliva.
Immunoassays Market Information
Immunoassays are a large market, globally worth $20.8 billion.
The overall market for immunoassays is highly competitive and growing slowly, but has specific areas of opportunity that will be maximized. Many of the market’s tests are mature and have been available for years or decades. Kalorama Information’s Immunoassay Markets puts the global market into perspective and profiles the many companies competing in the field of immunoassays.
Significant growth opportunities in the immunoassay market may be possible through further innovations. This includes both new platforms and novel biomarkers. The attractive opportunities these innovations may make possible have attracted many diagnostics companies.
Immunoassays are basic, long-standing tests existing in laboratories worldwide. Globally, prospects for market growth are good in certain geographical regions (developing countries).
Facets such as economics and increased health insurance availability is fueling market growth in developing countries, making them promising market segments. Many companies are targeting these markets, including major worldwide diagnostic companies as well as smaller ones. Future testing growth in these markets will occur in existing technology (ELISA and lateral flow tests).
Immunoassay innovations are expanding the market in new and emerging disease areas, noted in Immunoassay Markets. Kalorama details these innovations in immunoassays in this report, and highlights three in particular: GI and transplant management in medical condition assays, and saliva-based testing as an interesting and innovative vehicle.
NEW White Paper: 101 Companies in Immunoassays
New developments are designed to make multiplexing possible, to miniaturize the platforms for point-of-care, and to identify and develop assays for novel biomarkets; thus, further expanding the potential of immunoassays for the future…
Industry News – Who’s Leading in Immunoassays?
Leading names in immunoassays will not surprise, and leading companies often lead in IVD as well. Kalorama’s latest reporting indicates that, together, Roche, Abbott, Siemens Healthineers, Beckman Coulter, and Alere lead immunoassays, earning over 40% of the market. Kalorama’s Immunoassay Markets reports that this market share cuts accorss different disease categories, meaning some leading companies in immunoassays may not appear on our list.